Stock MNOV MEDICINOVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-03 pm EDT 		5-day change 1st Jan Change
1.47 USD +8.09% Intraday chart for MediciNova, Inc. +9.70% -2.00%
Jun. 03 MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 in Glioblastoma Patients At the American Society of Clinical Oncology Annual Meeting 2024 CI
May. 20 MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Eye Cancer CI

Evolution of the average Target Price on MediciNova, Inc.

Price target over the last 5 years

History of analyst recommendation changes

274c.w-HGt9pR3gVgaK9TStrtzU5sdLQZPRztfgzIFYs63xg.tIv1--wlgUMGBe0lI5O6lwU0Nex1aTGYBli8IN1gvHKIoP7CoCu9VS5f6g~725e64e9db108f81db1b32aa9ae9123e

Analyst Recommendations on MediciNova, Inc.

MediciNova Says Alcohol-Use Disorder Drug Reduced Rates of Heavy Drinking, Alcohol Craving in Mid-Stage Trial MT
Maxim Group Adjusts MediciNova Price Target to $6 From $10, Maintains Buy Rating MT
B. Riley Lowers MediciNova's Price Target to $6 from $11 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
MEDICINOVA : Maxim Starts MediciNova at Buy With $15 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.47 USD
Average target price
17 USD
Spread / Average Target
+1,056.46%
High Price Target
28 USD
Spread / Highest target
+1,804.76%
Low Price Target
6 USD
Spread / Lowest Target
+308.16%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MediciNova, Inc.

Maxim
B. Riley

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MNOV Stock
  4. Consensus MediciNova, Inc.